Explore more
News
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Qatar pushes back on ...
Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
The new research and development site will combine research, process development and clinical trial manufacturing ...
1don MSN
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback